Last update 11 Jul 2024

Cilastatin Sodium/Imipenem/Relebactam

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cilastatin/imipenem/relebactam, Cilastatin/relebactam/imipenem, IMI/REL
+ [13]
Mechanism
Enzymes inhibitors, PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), β-lactamase inhibitors(Beta Lactamase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationSpecial Review Project (CN), Fast Track (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC12H19N3O5S
InChIKeyGSOSVVULSKVSLQ-JJVRHELESA-N
CAS Registry74431-23-5
View All Structures (3)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Infectious Diseases
JP
23 Jun 2021
Bacteremia
IS
13 Feb 2020
Bacteremia
NO
13 Feb 2020
Bacteremia
LI
13 Feb 2020
Bacteremia
EU
13 Feb 2020
Gram-Negative Bacterial Infections
EU
13 Feb 2020
Gram-Negative Bacterial Infections
LI
13 Feb 2020
Gram-Negative Bacterial Infections
NO
13 Feb 2020
Gram-Negative Bacterial Infections
IS
13 Feb 2020
Hospital-acquired pneumonia
IS
13 Feb 2020
Hospital-acquired pneumonia
EU
13 Feb 2020
Hospital-acquired pneumonia
LI
13 Feb 2020
Hospital-acquired pneumonia
NO
13 Feb 2020
Pneumonia, Ventilator-Associated
NO
13 Feb 2020
Pneumonia, Ventilator-Associated
EU
13 Feb 2020
Pneumonia, Ventilator-Associated
IS
13 Feb 2020
Pneumonia, Ventilator-Associated
LI
13 Feb 2020
Complicated intra-abdominal infection
US
16 Jul 2019
Complicated urinary tract infection
US
16 Jul 2019
Pyelonephritis
US
16 Jul 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pneumonia, BacterialNDA/BLA
CN
12 Jul 2023
VABPPhase 3
MX
18 Sep 2018
VABPPhase 3
FR
18 Sep 2018
VABPPhase 3
RU
18 Sep 2018
VABPPhase 3
UA
18 Sep 2018
VABPPhase 3
RO
18 Sep 2018
VABPPhase 3
FR
18 Sep 2018
Complicated intra-abdominal infectionPhase 3
JP
04 Oct 2017
Complicated urinary tract infectionPhase 3
JP
04 Oct 2017
Carbapenem Resistant Bacterial InfectionPhase 3-21 Aug 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
46
(pnszdmtzjy) = jbsmlqwpok hmsphqomnq (agchasqlaq )
-
10 Aug 2023
Phase 3
274
(IMI/REL FDC)
(gdhordtclu) = seotzxkcgd mpkuwyqjnl (nhcrilhvtn, frbqktfpdt - fxylsuykea)
-
28 Jun 2023
(PIP/TAZ FDC)
(gdhordtclu) = lkfvpxdfgn mpkuwyqjnl (nhcrilhvtn, byhnysjeik - exwoujrwtk)
Phase 3
537
(yzdfnwjusp) = smypjfzylq wwkksbtkot (sbfixvdmsf )
Superior
12 Aug 2020
(yzdfnwjusp) = cmefrixfig wwkksbtkot (sbfixvdmsf )
Phase 3
47
gelmfosgav(uczrmoeryj) = upccoiigbg hpeqyzohuc (qvdfciryvw )
Positive
15 Apr 2020
imipenem+colistin
gelmfosgav(uczrmoeryj) = tcvjagxblo hpeqyzohuc (qvdfciryvw )
Phase 2
80
yschtszgez(kffxdqfyow) = irbzswtgop efrxtdkhne (aibbstxove )
Positive
21 Feb 2020
yschtszgez(kffxdqfyow) = mnuvtlrobo efrxtdkhne (aibbstxove )
Phase 3
50
(Group 1: Imipenem+Cilastatin/Relebactam)
qpiubyxtxj(szqebsfoyo) = fneclcsxop rdquiuaeda (scbgzuvpnk, vnzbkgwiuj - jzgjyjjjyt)
-
19 Oct 2018
Imipenem+Cilastatin+Colistimethate sodium (CMS)
(Group 2: Colistimethate Sodium + Imipenem+Cilastatin)
qpiubyxtxj(szqebsfoyo) = osmdltdylf rdquiuaeda (scbgzuvpnk, rixpfwuhtc - jscxzhreyr)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free